World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

NS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children’s Hospital

Cision PR Newswire by Cision PR Newswire
June 23, 2026
in Press Releases - Lifestyle
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

PARAMUS, N.J., June 23, 2026 /PRNewswire/ — NS Pharma, Inc. (NS Pharma; Headquarters: Paramus, New Jersey; President: Yukiteru Sugiyama) announced today that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto, Japan; President: Toru Nakai), has entered into a Sponsored Research Agreement (SRA) with Boston Children’s Hospital (Headquarters: Boston, Massachusetts; Chief Executive Officer: Kevin B. Churchwell) for the purpose of developing innovative therapeutic drugs in the field of neurology. The agreement was facilitated by the NS Pharma Innovation Research Partnering (IRP) team, located in Cambridge, MA.


Logo for NS Pharma, Inc. (PRNewsfoto/NS Pharma, Inc.)

Following the initiation of the strategic collaboration announced in July 2025, Nippon Shinyaku has selected key research themes as proposed by Boston Children’s Hospital as joint research programs. Through co-creation, Nippon Shinyaku will integrate Boston Children’s Hospital’s world class research capabilities with the company’s drug discovery expertise to accelerate the creation of new neurologic therapeutic options for patients with unmet medical needs.

“This new agreement demonstrates meaningful collaborative progress towards furthering rare disease research and the benefits of our combined expertise,” said Dr. Yukiteru Sugiyama, NS Pharma President. “We look forward to continuing to deepen our alliance with Boston Children’s Hospital and setting a positive example of impactful partnership for our rare disease communities.”

About NS Pharma, Inc.
NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. NS Pharma is a registered trademark of the Nippon Shinyaku Co., Ltd. For more information, please visit nspharma.com.

US Media Contact: media@nspharma.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ns-pharma-parent-company-nippon-shinyaku-announces-sponsored-research-agreement-with-boston-childrens-hospital-302806785.html

SOURCE NS Pharma, Inc.

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • HKEX Launches Offshore RMB Bond Index

    0 shares
    Share 0 Tweet 0
  • Thunes Expands Real-Time Payouts to Bhutan, Unlocking the Nation’s Remittance Market

    0 shares
    Share 0 Tweet 0
  • Bloomberg Indices and HKEX Launch Co-branded Offshore RMB Bond Index Family to Support Growing Investor Demand in the Dim Sum Bond Market

    0 shares
    Share 0 Tweet 0
  • CANACCORD GENUITY GROUP INC. ANNOUNCES SALE OF ITS WEALTH MANAGEMENT BUSINESS IN THE UK & CROWN DEPENDENCIES TO CENTERBRIDGE PARTNERS, L.P. AND MUBADALA INVESTMENT COMPANY PJSC

    0 shares
    Share 0 Tweet 0
  • SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Portillo’s Inc. (NASDAQ: PTLO) — Investors Who Suffered Losses Are Encouraged to Contact the Firm.

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler